Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
Abstract Belantamab mafodotin, a monomethyl auristatin F (MMAF)-containing monoclonal antibody‐drug conjugate (ADC), demonstrated deep and durable responses in the DRiving Excellence in Approaches to Multiple Myeloma (DREAMM)‐1 and pivotal DREAMM‐2 studies in patients with relapsed/refractory multip...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , |
|---|---|
| Fformat: | Llyfr |
| Cyhoeddwyd: |
Wiley,
2023-10-01T00:00:00Z.
|
| Pynciau: | |
| Mynediad Ar-lein: | Connect to this object online. |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Rhyngrwyd
Connect to this object online.3rd Floor Main Library
| Rhif Galw: |
A1234.567 |
|---|---|
| Copi 1 | Ar gael |